StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
SLQT

SelectQuote, Inc.

SLQT NYSE Insurance Agents, Brokers & Service EDGAR ↗
$0.43
-0.00 -0.84%

Key statistics

from XBRL data in SEC filings
Market cap ⓘ
$75.5M
Revenue (TTM) ⓘ
$1.62B
Net income (TTM) ⓘ
$62.2M
EPS (TTM) ⓘ
$-0.06
P/E ratio ⓘ
—
Dividend yield ⓘ
458.59%
Free cash flow ⓘ
$27.6M
Cash ⓘ
$16.0M
Total assets ⓘ
$1.29B
Gross margin ⓘ
—
52-week range ⓘ
$0.38 – $2.22

AI briefing

from the latest 10-K, 10-Q and 8-K events

SelectQuote is a technology-enabled, direct-to-consumer distribution and engagement platform that sells insurance policies and healthcare services.

What they do

SelectQuote identifies consumers seeking insurance and places them with insurance carrier partners, earning commissions on policies sold rather than underwriting risk itself. It operates three reportable segments: Senior, Healthcare Services and Life, plus a de-emphasized Auto & Home business. Its proprietary platform uses AI and machine learning to source consumer leads across digital, radio, television and third-party channels and route them to sales agents.

Revenue drivers

  • Healthcare Services — Includes the SelectRx Patient-Centered Pharmacy Home accredited pharmacy and SelectPatient Management; it produced $193.5 million of fourth quarter fiscal 2026 revenue, the largest segment in that quarter.
  • Senior — Distributes senior health insurance, largely Medicare Advantage, from a panel of carriers and earns commissions; fourth quarter fiscal 2026 revenue was $72.5 million with 72,180 approved Medicare Advantage policies.
  • Life — Places life insurance policies with carrier partners for commissions; fourth quarter fiscal 2026 revenue was $47.9 million.
  • Auto & Home — Sells automobile and home insurance policies but has been de-emphasized and no longer represents a core area of focus.

Recent performance

Fourth quarter fiscal 2026 revenue was $321.7 million versus $345.1 million a year earlier, with a net loss of $(16.8) million compared to net income of $12.9 million in the prior-year quarter. Fourth quarter Adjusted EBITDA was $11.9 million versus $2.7 million a year earlier. Full fiscal year 2026 revenue was $1.6 billion with net income of $62.2 million, and operating cash flow was $31.9 million versus $11.7 million used in fiscal 2025.

Strategy

SelectQuote is expanding its healthcare services platform, particularly pharmacy services through SelectRx and chronic care management through SelectPatient Management, while de-emphasizing Auto & Home production. In fiscal 2026 it began investing in AI capabilities including contact center voice technology, AI-assisted software development and enterprise-wide productivity tools, stating AI-powered contact center technology expanded licensed agent capacity. Management says technology-enabled workstream efficiencies exiting 2026 are expected to drive annual expense savings of over $30 million. It also states its highest strategic priority is growing profitability and scaled cash flow and optimizing leverage and funding costs.

Risks

  • Carrier concentration — The company depends on a small group of insurance carrier partners for a substantial portion of its business, so losing or failing to develop those relationships could harm results.
  • Senior carrier dependence — Its business is substantially dependent on revenue from Senior health insurance carrier partners, and carrier partners can change sales strategies or underwriting practices.
  • Enrollment windows — If the ability to enroll individuals during the Annual Enrollment Period and Open Enrollment Period is impeded, the business will be harmed.
  • Lead acquisition — The business depends on obtaining a large quantity of quality insurance sales leads in a cost-effective manner through marketing and third-party channels.

Outlook

For fiscal year 2027, management guides revenue of $1.35 billion to $1.45 billion and Adjusted EBITDA of $90 million to $115 million, with operating cash flow expected to be more than $60 million. Management expects full-year 2027 operating cash flow to approximately double, with free cash flow generation of around $50 million. It also cites a SelectRx run-rate Adjusted EBITDA of nearly $50 million exiting fiscal 2026.

Recent SEC filings

40 most recent
Annual, quarterly & current reports